{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semax-glp1-gut","title":"Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to persistent nausea, bloating, and in some cases diagnosed gastroparesis. The stomach muscles and vagus nerve signaling weaken or desynchronize. Repair of motility and gut-brain communication lags behind the drug-induced suppression. When breakdown outruns repair, symptoms persist even after dose adjustments.\n\n## Why Semax might help you\n\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline can blunt neural plasticity along the gut-brain axis; autonomic signaling to the stomach may stay impaired after GLP-1 exposure.\n3. What Semax is studied to do: It is studied for BDNF upregulation and neural support in brain regions tied to autonomic control.\n4. Therefore for you: If neural repair at the gut-brain interface is part of your problem, Semax is discussed because it targets repair pathways rather than further suppressing motility signals.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists deliver metabolic benefits through appetite suppression and slowed gastric emptying. They suppress hunger signals and reduce overall caloric load. For someone with GLP-1 gut damage, this creates a tradeoff: the same slowing that aids weight control can worsen motility issues and delay gastric repair. The drug reduces metabolic load but trades off direct support for gut motility recovery.\n\n## How these fit together\n\nSingle-compound focus on Semax. The neural / cognitive layer targeted by Semax sits alongside the motility suppression from GLP-1 agonists. Semax addresses BDNF-linked plasticity that may support autonomic recovery, while GLP-1 agonists handle metabolic demand. No multi-peptide layering is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work in rats shows Semax increases gastric mucosal resistance to ethanol and stress-induced ulcers. One 2009 study found protective effects at certain doses via peripheral mechanisms. Human data on Semax for any gut condition is absent. BDNF upregulation appears in multiple rat hippocampal and basal forebrain studies after intranasal dosing. One small human stroke cohort (110 patients) reported plasma BDNF rises with Semax courses. No trials link Semax directly to gastroparesis reversal or GLP-1 side-effect mitigation.\n\n## What scientists say\n\nRussian researchers have published on Semax as an ACTH fragment analog that stimulates BDNF synthesis in astrocytes and modulates melanocortin pathways. Western reviews note limited replication outside Russia and call for larger controlled trials. No statements address gastroparesis or GLP-1 gut effects.\n\n## What people say on Reddit\n\nAnecdotal reports on peptide forums mention stacking Semax with GLP-1 agonists for focus or mood support during weight loss. Users describe subjective cognitive clarity but rarely claim gut motility improvements. No controlled user data exists.\n\n## What people say on X\n\nPosts occasionally pair Semax with semaglutide for gut-brain axis discussion. Comments focus on nootropic effects or neuroprotection rather than direct gastroparesis relief. Volume remains low and unverified.\n\n## What we do not know\n\nNo human trials test Semax in patients with GLP-1-induced gastroparesis. Long-term effects on human gastric motility are unknown. Dose-response data for gut outcomes do not exist outside rat ulcer models. Interaction with ongoing GLP-1 therapy lacks study.\n\n## Safety and limits\n\nSemax is registered in Russia for neurological indications but lacks FDA approval. Reported human use shows good short-term tolerability in available studies. Animal gastroprotective findings do not translate directly to human gastroparesis management. Individuals should consult clinicians before considering any peptide alongside GLP-1 therapy.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-glp1-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax showed gastroprotective effects against ethanol and stress ulcers in rat models at doses 0.06–3.7 µmol/kg.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct gut-related data for Semax; remains animal-only.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF protein and mRNA in rat basal forebrain and hippocampus after intranasal administration.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanistic finding repeated across rodent studies.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"A Russian cohort of 110 stroke patients receiving Semax courses showed increased plasma BDNF levels.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"One of few quantified human BDNF responses; not gut-related.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GLP-1 agonists cause delayed gastric emptying and reported gastroparesis cases in post-marketing data.","section":"What's breaking down if you have GLP-1 gut damage / gastroparesis","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Establishes the core clinical tradeoff for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials exist testing Semax for gastroparesis or GLP-1 agonist side effects.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Highlights evidence gap for this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.3103/S0096392509040014","title":"The comparison of gastroprotective properties of Semax and its metabolites","quote":"Semax (MEHFPGP) was shown to increase gastric mucosal homeostasis to the action of such ulcerogenic factors as ethanol and stress.","summary":"2009 rat study comparing Semax and metabolites in ulcer models.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"5ed454d097b629944351211626490a298416f960cfb976016615299c2c39e839"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases BDNF levels...","quote":"Semax stimulates the synthesis of brain-derived neurotrophic factor (BDNF)... in astrocytes cultured from rat basal forebrain.","summary":"Demonstrates BDNF increase and specific binding in rat brain tissue.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"ok","quote_status":"unverified","prev":"5ed454d097b629944351211626490a298416f960cfb976016615299c2c39e839","hash":"675e8f9c938ab5f4f534875c38b03d0547c53915323071e1aa76b84ae2dc532c"},{"id":"s3","type":"pubmed","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Another study in 110 patients with stroke reported that treatment with semax (2 courses 6000 µg/day for 10 days with 20-day interval) increased plasma BDNF levels.","summary":"Summary of limited human stroke data showing BDNF response.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"ok","quote_status":"unverified","prev":"675e8f9c938ab5f4f534875c38b03d0547c53915323071e1aa76b84ae2dc532c","hash":"495499df974634464b575320ca70bef69501e7c0fe11491f2312e755c70948c8"},{"id":"s4","type":"medical","url":"https://www.gastroenterologyadvisor.com/features/what-we-know-about-semaglutide-adverse-events-and-gastroparesis-part-1/","title":"What We Know About Semaglutide Adverse Events and Gastroparesis","quote":"GLP-1 is a regulator of appetite and caloric intake and is known to have various drug interactions due to delayed gastric emptying as a result of therapy.","summary":"Clinical overview of GLP-1 GI side effects including gastroparesis reports.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"dead","quote_status":"unverified","prev":"495499df974634464b575320ca70bef69501e7c0fe11491f2312e755c70948c8","hash":"7df26814dc63ac75687990b23c04a960a8ba9a513bd6754d9895956ad91f1e1f"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:10:57.133Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways","register":"source_ledger","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to persistent nausea, bloating, and in some cases diagnosed gastroparesis. The stomach muscles and vagus nerve signaling weaken or desynchronize. Repair of motility and gut-brain communication lags behind the drug-induced suppression. When breakdown outruns repair, symptoms persist even after dose adjustments.\n\n## Why Semax might help you\n\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline can blunt neural plasticity along the gut-brain axis; autonomic signaling to the stomach may stay impaired after GLP-1 exposure.\n3. What Semax is studied to do: It is studied for BDNF upregulation and neural support in brain regions tied to autonomic control.\n4. Therefore for you: If neural repair at the gut-brain interface is part of your problem, Semax is discussed because it targets repair pathways rather than further suppressing motility signals.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists deliver metabolic benefits through appetite suppression and slowed gastric emptying. They suppress hunger signals and reduce overall caloric load. For someone with GLP-1 gut damage, this creates a tradeoff: the same slowing that aids weight control can worsen motility issues and delay gastric repair. The drug reduces metabolic load but trades off direct support for gut motility recovery.\n\n## How these fit together\n\nSingle-compound focus on Semax. The neural / cognitive layer targeted by Semax sits alongside the motility suppression from GLP-1 agonists. Semax addresses BDNF-linked plasticity that may support autonomic recovery, while GLP-1 agonists handle metabolic demand. No multi-peptide layering is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work in rats shows Semax increases gastric mucosal resistance to ethanol and stress-induced ulcers. One 2009 study found protective effects at certain doses via peripheral mechanisms. Human data on Semax for any gut condition is absent. BDNF upregulation appears in multiple rat hippocampal and basal forebrain studies after intranasal dosing. One small human stroke cohort (110 patients) reported plasma BDNF rises with Semax courses. No trials link Semax directly to gastroparesis reversal or GLP-1 side-effect mitigation.\n\n## What scientists say\n\nRussian researchers have published on Semax as an ACTH fragment analog that stimulates BDNF synthesis in astrocytes and modulates melanocortin pathways. Western reviews note limited replication outside Russia and call for larger controlled trials. No statements address gastroparesis or GLP-1 gut effects.\n\n## What people say on Reddit\n\nAnecdotal reports on peptide forums mention stacking Semax with GLP-1 agonists for focus or mood support during weight loss. Users describe subjective cognitive clarity but rarely claim gut motility improvements. No controlled user data exists.\n\n## What people say on X\n\nPosts occasionally pair Semax with semaglutide for gut-brain axis discussion. Comments focus on nootropic effects or neuroprotection rather than direct gastroparesis relief. Volume remains low and unverified.\n\n## What we do not know\n\nNo human trials test Semax in patients with GLP-1-induced gastroparesis. Long-term effects on human gastric motility are unknown. Dose-response data for gut outcomes do not exist outside rat ulcer models. Interaction with ongoing GLP-1 therapy lacks study.\n\n## Safety and limits\n\nSemax is registered in Russia for neurological indications but lacks FDA approval. Reported human use shows good short-term tolerability in available studies. Animal gastroprotective findings do not translate directly to human gastroparesis management. Individuals should consult clinicians before considering any peptide alongside GLP-1 therapy.","claims":[{"id":"c1","text":"Semax showed gastroprotective effects against ethanol and stress ulcers in rat models at doses 0.06–3.7 µmol/kg.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct gut-related data for Semax; remains animal-only.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF protein and mRNA in rat basal forebrain and hippocampus after intranasal administration.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanistic finding repeated across rodent studies.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"A Russian cohort of 110 stroke patients receiving Semax courses showed increased plasma BDNF levels.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"One of few quantified human BDNF responses; not gut-related.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GLP-1 agonists cause delayed gastric emptying and reported gastroparesis cases in post-marketing data.","section":"What's breaking down if you have GLP-1 gut damage / gastroparesis","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Establishes the core clinical tradeoff for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials exist testing Semax for gastroparesis or GLP-1 agonist side effects.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Highlights evidence gap for this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.3103/S0096392509040014","title":"The comparison of gastroprotective properties of Semax and its metabolites","quote":"Semax (MEHFPGP) was shown to increase gastric mucosal homeostasis to the action of such ulcerogenic factors as ethanol and stress.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases BDNF levels...","quote":"Semax stimulates the synthesis of brain-derived neurotrophic factor (BDNF)... in astrocytes cultured from rat basal forebrain.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Another study in 110 patients with stroke reported that treatment with semax (2 courses 6000 µg/day for 10 days with 20-day interval) increased plasma BDNF levels.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://www.gastroenterologyadvisor.com/features/what-we-know-about-semaglutide-adverse-events-and-gastroparesis-part-1/","title":"What We Know About Semaglutide Adverse Events and Gastroparesis","quote":"GLP-1 is a regulator of appetite and caloric intake and is known to have various drug interactions due to delayed gastric emptying as a result of therapy.","link_status":"dead","quote_status":"unverified"}]},"rationale":"","tokens_in":13959,"tokens_out":3021,"cost":0.02500125,"prev_hash":"genesis","hash":"58e3f8bd89bdde48cc9ce1ac446b8b849a288d93579cf69c717d2c4451edb9ed"}],"provenance":[{"ts":"2026-06-30T00:10:57.133Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Glp1 Gut\nSlug: semax-glp1-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"GLP-1 gut damage / gastroparesis\",\"condition_key\":\"glp1-gut-damage\",\"primary_peptide\":\"semax\",\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have GLP-1 gut damage / gastroparesis\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\",\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\\n2. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n3. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating sympt","response":"{\n  \"slug\": \"semax-glp1-gut\",\n  \"title\": \"Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways\",\n  \"body\": \"## What's breaking down if you have GLP-1 gut damage / gastroparesis\\n\\nGLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to persistent nausea, bloating, and in some cases diagnosed gastroparesis. The stomach muscles and vagus nerve signaling weaken or desynchronize. Repair of motility and gut-brain communication lags behind the drug-induced suppression. When breakdown outruns repair, symptoms persist even after dose adjustments.\\n\\n## Why Semax might help you\\n\\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\\n2. What keeps failing: BDNF decline can blunt neural plasticity along the gut-brain axis; autonomic signaling to the stomach may stay impaired after GLP-1 exposure.\\n3. What Semax is studied to do: It is studied for BDNF upregulation and neural support in brain regions tied to autonomic control.\\n4. Therefore for you: If neural repair at the gut-brain interface is part of your problem, Semax is discussed because it targets repair pathways rather than further suppressing motility signals.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists deliver metabolic benefits through appetite suppression and slowed gastric emptying. They suppress hunger signals and reduce overall caloric load. For someone with GLP-1 gut damage, this creates a tradeoff: the same slowing that aids weight control can worsen motility issues and delay gastric repair. The drug reduces metabolic load but trades off direct support for gut motility recovery.\\n\\n## How these fit together\\n\\nSingle-compound focus on Semax. The neural / cognitive layer targeted by Semax sits alongside the motility suppression from GLP-1 agonists. Semax addresses BDNF-linked plasticity that may support autonomic recovery, while GLP-1 agonists handle metabolic demand. No multi-pepti","tokens_in":13959,"tokens_out":3021,"cost":0,"prev":"genesis","hash":"78916f2de3720446820336f41d59162257c3846c9847e24306b3d6b7de91873c"},{"ts":"2026-07-17T02:41:54.149Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-glp1-gut","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"78916f2de3720446820336f41d59162257c3846c9847e24306b3d6b7de91873c","hash":"8f0f078ba6688939221cacd7841f75f806f766af8775cfda4bc5c0e839f9f748"}],"energy":{"passes":2,"tokens_in":13959,"tokens_out":3021,"tokens_total":16980,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8f0f078ba6688939221cacd7841f75f806f766af8775cfda4bc5c0e839f9f748"},"posted_at":"2026-06-29T21:33:16.725Z","created_at":"2026-06-29T21:33:16.725Z","updated_at":"2026-07-17T02:41:54.149Z","machine":{"shape":"article.machine/v1","slug":"semax-glp1-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-glp1-gut","json":"https://miscsubjects.com/api/articles/semax-glp1-gut","bundle":"https://miscsubjects.com/api/articles/semax-glp1-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semax-glp1-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-glp1-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-glp1-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-glp1-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-glp1-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-glp1-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-glp1-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-glp1-gut","json":"/api/articles/semax-glp1-gut","markdown":"/api/articles/semax-glp1-gut/bundle?format=markdown","skill":"/api/articles/semax-glp1-gut/skill","topology":"/api/articles/semax-glp1-gut/topology","versions":"/api/articles/semax-glp1-gut/revisions","invocations":"/api/articles/semax-glp1-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-glp1-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1f9f1ba59de883eb0e0dddee9659697cb6bba55eadaec469db5e63c0d41d7a5f","object":{"object_type":"article-object","identity":{"id":"article:semax-glp1-gut","slug":"semax-glp1-gut","title":"Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/semax-glp1-gut","role":"explain","audience":"human"},"skill":{"route":"/api/articles/semax-glp1-gut/skill","role":"direct behavior","audience":"model","content":"---\nname: semax-glp1-gut\ndescription: Apply the Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways\n\nThis Skill is the behavioral expression of [the canonical article](/a/semax-glp1-gut). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/semax-glp1-gut.\n- Read claims and relationships at /api/articles/semax-glp1-gut/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have GLP-1 gut damage / gastroparesis GLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to persistent nausea, bloating, and in some cases diagnosed gastroparesis. The stomach muscles \n\n## Representations\n\n- Human: /a/semax-glp1-gut\n- JSON: /api/articles/semax-glp1-gut\n- Relationships: /api/articles/semax-glp1-gut/topology\n- History: /api/articles/semax-glp1-gut/revisions\n"},"json":{"route":"/api/articles/semax-glp1-gut","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/semax-glp1-gut/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","semax","glp1","gut"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/semax-glp1-gut/invocations?status=success","failure_events":"/api/articles/semax-glp1-gut/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"semax-glp1-gut","title":"Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to persistent nausea, bloating, and in some cases diagnosed gastroparesis. The stomach muscles and vagus nerve signaling weaken or desynchronize. Repair of motility and gut-brain communication lags behind the drug-induced suppression. When breakdown outruns repair, symptoms persist even after dose adjustments.\n\n## Why Semax might help you\n\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline can blunt neural plasticity along the gut-brain axis; autonomic signaling to the stomach may stay impaired after GLP-1 exposure.\n3. What Semax is studied to do: It is studied for BDNF upregulation and neural support in brain regions tied to autonomic control.\n4. Therefore for you: If neural repair at the gut-brain interface is part of your problem, Semax is discussed because it targets repair pathways rather than further suppressing motility signals.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists deliver metabolic benefits through appetite suppression and slowed gastric emptying. They suppress hunger signals and reduce overall caloric load. For someone with GLP-1 gut damage, this creates a tradeoff: the same slowing that aids weight control can worsen motility issues and delay gastric repair. The drug reduces metabolic load but trades off direct support for gut motility recovery.\n\n## How these fit together\n\nSingle-compound focus on Semax. The neural / cognitive layer targeted by Semax sits alongside the motility suppression from GLP-1 agonists. Semax addresses BDNF-linked plasticity that may support autonomic recovery, while GLP-1 agonists handle metabolic demand. No multi-peptide layering is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work in rats shows Semax increases gastric mucosal resistance to ethanol and stress-induced ulcers. One 2009 study found protective effects at certain doses via peripheral mechanisms. Human data on Semax for any gut condition is absent. BDNF upregulation appears in multiple rat hippocampal and basal forebrain studies after intranasal dosing. One small human stroke cohort (110 patients) reported plasma BDNF rises with Semax courses. No trials link Semax directly to gastroparesis reversal or GLP-1 side-effect mitigation.\n\n## What scientists say\n\nRussian researchers have published on Semax as an ACTH fragment analog that stimulates BDNF synthesis in astrocytes and modulates melanocortin pathways. Western reviews note limited replication outside Russia and call for larger controlled trials. No statements address gastroparesis or GLP-1 gut effects.\n\n## What people say on Reddit\n\nAnecdotal reports on peptide forums mention stacking Semax with GLP-1 agonists for focus or mood support during weight loss. Users describe subjective cognitive clarity but rarely claim gut motility improvements. No controlled user data exists.\n\n## What people say on X\n\nPosts occasionally pair Semax with semaglutide for gut-brain axis discussion. Comments focus on nootropic effects or neuroprotection rather than direct gastroparesis relief. Volume remains low and unverified.\n\n## What we do not know\n\nNo human trials test Semax in patients with GLP-1-induced gastroparesis. Long-term effects on human gastric motility are unknown. Dose-response data for gut outcomes do not exist outside rat ulcer models. Interaction with ongoing GLP-1 therapy lacks study.\n\n## Safety and limits\n\nSemax is registered in Russia for neurological indications but lacks FDA approval. Reported human use shows good short-term tolerability in available studies. Animal gastroprotective findings do not translate directly to human gastroparesis management. Individuals should consult clinicians before considering any peptide alongside GLP-1 therapy.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-glp1-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax showed gastroprotective effects against ethanol and stress ulcers in rat models at doses 0.06–3.7 µmol/kg.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct gut-related data for Semax; remains animal-only.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF protein and mRNA in rat basal forebrain and hippocampus after intranasal administration.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanistic finding repeated across rodent studies.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"A Russian cohort of 110 stroke patients receiving Semax courses showed increased plasma BDNF levels.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"One of few quantified human BDNF responses; not gut-related.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GLP-1 agonists cause delayed gastric emptying and reported gastroparesis cases in post-marketing data.","section":"What's breaking down if you have GLP-1 gut damage / gastroparesis","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Establishes the core clinical tradeoff for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials exist testing Semax for gastroparesis or GLP-1 agonist side effects.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Highlights evidence gap for this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.3103/S0096392509040014","title":"The comparison of gastroprotective properties of Semax and its metabolites","quote":"Semax (MEHFPGP) was shown to increase gastric mucosal homeostasis to the action of such ulcerogenic factors as ethanol and stress.","summary":"2009 rat study comparing Semax and metabolites in ulcer models.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"5ed454d097b629944351211626490a298416f960cfb976016615299c2c39e839"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases BDNF levels...","quote":"Semax stimulates the synthesis of brain-derived neurotrophic factor (BDNF)... in astrocytes cultured from rat basal forebrain.","summary":"Demonstrates BDNF increase and specific binding in rat brain tissue.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"ok","quote_status":"unverified","prev":"5ed454d097b629944351211626490a298416f960cfb976016615299c2c39e839","hash":"675e8f9c938ab5f4f534875c38b03d0547c53915323071e1aa76b84ae2dc532c"},{"id":"s3","type":"pubmed","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Another study in 110 patients with stroke reported that treatment with semax (2 courses 6000 µg/day for 10 days with 20-day interval) increased plasma BDNF levels.","summary":"Summary of limited human stroke data showing BDNF response.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"ok","quote_status":"unverified","prev":"675e8f9c938ab5f4f534875c38b03d0547c53915323071e1aa76b84ae2dc532c","hash":"495499df974634464b575320ca70bef69501e7c0fe11491f2312e755c70948c8"},{"id":"s4","type":"medical","url":"https://www.gastroenterologyadvisor.com/features/what-we-know-about-semaglutide-adverse-events-and-gastroparesis-part-1/","title":"What We Know About Semaglutide Adverse Events and Gastroparesis","quote":"GLP-1 is a regulator of appetite and caloric intake and is known to have various drug interactions due to delayed gastric emptying as a result of therapy.","summary":"Clinical overview of GLP-1 GI side effects including gastroparesis reports.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:10:55.111Z","link_status":"dead","quote_status":"unverified","prev":"495499df974634464b575320ca70bef69501e7c0fe11491f2312e755c70948c8","hash":"7df26814dc63ac75687990b23c04a960a8ba9a513bd6754d9895956ad91f1e1f"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:10:57.133Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways","register":"source_ledger","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to persistent nausea, bloating, and in some cases diagnosed gastroparesis. The stomach muscles and vagus nerve signaling weaken or desynchronize. Repair of motility and gut-brain communication lags behind the drug-induced suppression. When breakdown outruns repair, symptoms persist even after dose adjustments.\n\n## Why Semax might help you\n\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline can blunt neural plasticity along the gut-brain axis; autonomic signaling to the stomach may stay impaired after GLP-1 exposure.\n3. What Semax is studied to do: It is studied for BDNF upregulation and neural support in brain regions tied to autonomic control.\n4. Therefore for you: If neural repair at the gut-brain interface is part of your problem, Semax is discussed because it targets repair pathways rather than further suppressing motility signals.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists deliver metabolic benefits through appetite suppression and slowed gastric emptying. They suppress hunger signals and reduce overall caloric load. For someone with GLP-1 gut damage, this creates a tradeoff: the same slowing that aids weight control can worsen motility issues and delay gastric repair. The drug reduces metabolic load but trades off direct support for gut motility recovery.\n\n## How these fit together\n\nSingle-compound focus on Semax. The neural / cognitive layer targeted by Semax sits alongside the motility suppression from GLP-1 agonists. Semax addresses BDNF-linked plasticity that may support autonomic recovery, while GLP-1 agonists handle metabolic demand. No multi-peptide layering is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work in rats shows Semax increases gastric mucosal resistance to ethanol and stress-induced ulcers. One 2009 study found protective effects at certain doses via peripheral mechanisms. Human data on Semax for any gut condition is absent. BDNF upregulation appears in multiple rat hippocampal and basal forebrain studies after intranasal dosing. One small human stroke cohort (110 patients) reported plasma BDNF rises with Semax courses. No trials link Semax directly to gastroparesis reversal or GLP-1 side-effect mitigation.\n\n## What scientists say\n\nRussian researchers have published on Semax as an ACTH fragment analog that stimulates BDNF synthesis in astrocytes and modulates melanocortin pathways. Western reviews note limited replication outside Russia and call for larger controlled trials. No statements address gastroparesis or GLP-1 gut effects.\n\n## What people say on Reddit\n\nAnecdotal reports on peptide forums mention stacking Semax with GLP-1 agonists for focus or mood support during weight loss. Users describe subjective cognitive clarity but rarely claim gut motility improvements. No controlled user data exists.\n\n## What people say on X\n\nPosts occasionally pair Semax with semaglutide for gut-brain axis discussion. Comments focus on nootropic effects or neuroprotection rather than direct gastroparesis relief. Volume remains low and unverified.\n\n## What we do not know\n\nNo human trials test Semax in patients with GLP-1-induced gastroparesis. Long-term effects on human gastric motility are unknown. Dose-response data for gut outcomes do not exist outside rat ulcer models. Interaction with ongoing GLP-1 therapy lacks study.\n\n## Safety and limits\n\nSemax is registered in Russia for neurological indications but lacks FDA approval. Reported human use shows good short-term tolerability in available studies. Animal gastroprotective findings do not translate directly to human gastroparesis management. Individuals should consult clinicians before considering any peptide alongside GLP-1 therapy.","claims":[{"id":"c1","text":"Semax showed gastroprotective effects against ethanol and stress ulcers in rat models at doses 0.06–3.7 µmol/kg.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct gut-related data for Semax; remains animal-only.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF protein and mRNA in rat basal forebrain and hippocampus after intranasal administration.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanistic finding repeated across rodent studies.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"A Russian cohort of 110 stroke patients receiving Semax courses showed increased plasma BDNF levels.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"One of few quantified human BDNF responses; not gut-related.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GLP-1 agonists cause delayed gastric emptying and reported gastroparesis cases in post-marketing data.","section":"What's breaking down if you have GLP-1 gut damage / gastroparesis","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Establishes the core clinical tradeoff for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials exist testing Semax for gastroparesis or GLP-1 agonist side effects.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Highlights evidence gap for this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:10:56.390Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.3103/S0096392509040014","title":"The comparison of gastroprotective properties of Semax and its metabolites","quote":"Semax (MEHFPGP) was shown to increase gastric mucosal homeostasis to the action of such ulcerogenic factors as ethanol and stress.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases BDNF levels...","quote":"Semax stimulates the synthesis of brain-derived neurotrophic factor (BDNF)... in astrocytes cultured from rat basal forebrain.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Another study in 110 patients with stroke reported that treatment with semax (2 courses 6000 µg/day for 10 days with 20-day interval) increased plasma BDNF levels.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://www.gastroenterologyadvisor.com/features/what-we-know-about-semaglutide-adverse-events-and-gastroparesis-part-1/","title":"What We Know About Semaglutide Adverse Events and Gastroparesis","quote":"GLP-1 is a regulator of appetite and caloric intake and is known to have various drug interactions due to delayed gastric emptying as a result of therapy.","link_status":"dead","quote_status":"unverified"}]},"rationale":"","tokens_in":13959,"tokens_out":3021,"cost":0.02500125,"prev_hash":"genesis","hash":"58e3f8bd89bdde48cc9ce1ac446b8b849a288d93579cf69c717d2c4451edb9ed"}],"provenance":[{"ts":"2026-06-30T00:10:57.133Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Glp1 Gut\nSlug: semax-glp1-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"GLP-1 gut damage / gastroparesis\",\"condition_key\":\"glp1-gut-damage\",\"primary_peptide\":\"semax\",\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have GLP-1 gut damage / gastroparesis\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\",\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\\n2. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n3. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating sympt","response":"{\n  \"slug\": \"semax-glp1-gut\",\n  \"title\": \"Semax for GLP-1 Gut Damage: Evidence on Neural and Gastroprotective Pathways\",\n  \"body\": \"## What's breaking down if you have GLP-1 gut damage / gastroparesis\\n\\nGLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to persistent nausea, bloating, and in some cases diagnosed gastroparesis. The stomach muscles and vagus nerve signaling weaken or desynchronize. Repair of motility and gut-brain communication lags behind the drug-induced suppression. When breakdown outruns repair, symptoms persist even after dose adjustments.\\n\\n## Why Semax might help you\\n\\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\\n2. What keeps failing: BDNF decline can blunt neural plasticity along the gut-brain axis; autonomic signaling to the stomach may stay impaired after GLP-1 exposure.\\n3. What Semax is studied to do: It is studied for BDNF upregulation and neural support in brain regions tied to autonomic control.\\n4. Therefore for you: If neural repair at the gut-brain interface is part of your problem, Semax is discussed because it targets repair pathways rather than further suppressing motility signals.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nGLP-1 agonists deliver metabolic benefits through appetite suppression and slowed gastric emptying. They suppress hunger signals and reduce overall caloric load. For someone with GLP-1 gut damage, this creates a tradeoff: the same slowing that aids weight control can worsen motility issues and delay gastric repair. The drug reduces metabolic load but trades off direct support for gut motility recovery.\\n\\n## How these fit together\\n\\nSingle-compound focus on Semax. The neural / cognitive layer targeted by Semax sits alongside the motility suppression from GLP-1 agonists. Semax addresses BDNF-linked plasticity that may support autonomic recovery, while GLP-1 agonists handle metabolic demand. No multi-pepti","tokens_in":13959,"tokens_out":3021,"cost":0,"prev":"genesis","hash":"78916f2de3720446820336f41d59162257c3846c9847e24306b3d6b7de91873c"},{"ts":"2026-07-17T02:41:54.149Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-glp1-gut","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"78916f2de3720446820336f41d59162257c3846c9847e24306b3d6b7de91873c","hash":"8f0f078ba6688939221cacd7841f75f806f766af8775cfda4bc5c0e839f9f748"}],"energy":{"passes":2,"tokens_in":13959,"tokens_out":3021,"tokens_total":16980,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8f0f078ba6688939221cacd7841f75f806f766af8775cfda4bc5c0e839f9f748"},"posted_at":"2026-06-29T21:33:16.725Z","created_at":"2026-06-29T21:33:16.725Z","updated_at":"2026-07-17T02:41:54.149Z","machine":{"shape":"article.machine/v1","slug":"semax-glp1-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-glp1-gut","json":"https://miscsubjects.com/api/articles/semax-glp1-gut","bundle":"https://miscsubjects.com/api/articles/semax-glp1-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semax-glp1-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-glp1-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-glp1-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-glp1-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-glp1-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-glp1-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-glp1-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-glp1-gut","json":"/api/articles/semax-glp1-gut","markdown":"/api/articles/semax-glp1-gut/bundle?format=markdown","skill":"/api/articles/semax-glp1-gut/skill","topology":"/api/articles/semax-glp1-gut/topology","versions":"/api/articles/semax-glp1-gut/revisions","invocations":"/api/articles/semax-glp1-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-glp1-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1f9f1ba59de883eb0e0dddee9659697cb6bba55eadaec469db5e63c0d41d7a5f"}}}